ClinicalTrials.gg
CompletedNCT07181785CHARTHERUpdated Sep 18, 2025

Molecular Characterization and Outcomes of Aggressive B-Cell Lymphomas.

An observational study in Diffuse Large B Cell Lymphoma (DLBCL), sponsored by Andrés José Maria Ferreri. Completed at 1 site in Italy. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-09-18.

Sponsored by Andrés José Maria Ferreri · Observational

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Other
Time perspective
Retrospective
Enrollment
555
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 166 studies in Lymphoma, Large B-Cell, Diffuse with a site in Italy — 31 open to participants now, 51 under way, 12 of them phase 3. Lymphoma, Large B-Cell, Diffuse · Italy.

Enrollment
5th of 22
555 · median 163
Started
2022
with 13 others
Observational
22 of 166
9 open now
Registered
157th of 166
by date

Among the 166 studies in Lymphoma, Large B-Cell, Diffuse with a site in Italy, this one is the 5th largest by enrollment of the 22 observational ones that give a count, is one of 14 that started in 2022, is one of 22 observational ones, and was the 157th registered.

Lymphoma, Large B-Cell, Diffuse

1,873 studies on the registry are indexed under Lymphoma, Large B-Cell, Diffuse; 359 are open to participants now.

Browse Lymphoma, Large B-Cell, Diffuse studies →

Open to participants now

31 of the 166 studies in Lymphoma, Large B-Cell, Diffuse with a site in Italy are open now. Recruiting first, the newest first:

26 more — sign in →

All 31 open studies →

A study can be open while its sites in Italy have not opened yet or have stopped. Only those recruiting at a site in Italy →

Who these studies take

Of the 265 Lymphoma, Large B-Cell, Diffuse studies recruiting now, 176 (66%) set no upper age limit and 51 (19%) stop at 75 or younger; 25 take children under 18; 7 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 166 studies in Lymphoma, Large B-Cell, Diffuse with a site in Italy, or all of them as a file.
02

Study summary

This is a retrospective analysis of the presence of chromosomal rearrangements involving MYC, BCL2 and BCL6 genes by FISH in a retrospective, single-center series of large B-cell lymphomas, in order to allow a better classifications of these cases according to the current WHO 2017 classification. If this evaluation will be confirmed as a reliable method to reclassify in different groups the evaluated tumors, it can be subsequently routinely apply to indicate the best treatment approaches in this high-risk setting of patients with a significant impact on patients' morbidity and mortality, and also on the health system and related costs.

03

Conditions studied

  • Diffuse Large B Cell Lymphoma (DLBCL)
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Adult subjects (> 18 years old) of any age and gender affected by large B-cell lymphomas

Eligibility criteria

  • -confirmed diagnosis of LBCL (i.e., DLBCL, HGBCL, unclassifiable B-cell lymphoma with features intermediate between DLBCL and BL), or aggressive B-cell lymphomas with blastoid morphology (excluding blastoid variant of mantle cell lymphoma and lymphoblastic lymphoma)
  • Histopathological diagnosis performed between 2000 and 2019.
  • sero-negativity
  • Age ≥18
  • Treatment with R-CHOP or other intensified polychemotherapy regimen
  • Availability of adequate histopathological samples at diagnosis for FISH analysis
  • Availability of clinical records and outcomes data

Exclusion criteria

  • Histologic diagnosis other than DLBCL or unclassifiable B-cell lymphoma with features intermediate between DLBCL and BL
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Observational model
Other
Time perspective
Retrospective
Enrollment
555 participants (actual)
Patient registry
No

Groups and cohorts

  • Adult subjects (> 18 years old) of any age and gender affected by large B-cell lymphoma.

    Histologically-confirmed diagnosis of LBCL (i.e., DLBCL, HGBCL, unclassifiable B-cell lymphoma with features intermediate between DLBCL and BL), or aggressive B-cell lymphomas with blastoid morphology (excluding blastoid variant of mantle cell lymphoma and lymphoblastic lymphoma) * Histopathological diagnosis performed between 2000 and 2019. * HIV sero-negativity * Age ≥18 * Treatment with R-CHOP or other intensified polychemotherapy regimen * Availability of adequate histopathological samples at diagnosis for FISH analysis * Availability of clinical records and outcomes data

    Combination Product: Treatments: anthracycline-based combinations followed or not by involved-field radiotherapy

Interventions

  • Combination productTreatments: anthracycline-based combinations followed or not by involved-field radiotherapy

    Anthracycline-based combinations followed or not by involved-field radiotherapy

06

What researchers measure

Primary outcomes

  1. Overall Survival (OS)

    Overall survival (OS) is time from the date of pathologic diagnosis until death from any cause or last follow-up, whichever occurs first.

    Time frame: From the date of pathologic diagnosis until death from any cause or last follow-up, whichever occurs first, assessed up to 60 months

Secondary outcomes

  1. Progression-free Survival (PFS)

    Progression-Free Survival (PFS) is the length of time during and after a disease treatment that a patient lives without the disease worsening or progressing

    Time frame: From the first day of treatment until relapse, progression, death , or last follow-up, whichever occurs first, assessed up to 60 months

  2. Overall Response Rate

    the Overall Response Rate (ORR) measures the percentage of patients whose disease shows a reduction in size or is eliminated after a specific treatment. It includes patients who achieve either a Complete Response (CR), where all signs of the lymphoma disappear, or a Partial Response (PR), where there is a significant reduction in tumor burden but some signs of the disease remain

    Time frame: From the first day of treatment until the date of first documented response assessment, typically within 6 months of treatment initiation

  3. Duration of response (DOR; partial response [PR] + complete remission [CR])

    Time from the date of first documented response (complete or partial) until disease progression, relapse, death from any cause, or last follow-up, whichever occurs first.

    Time frame: From the date of first documented response (CR or PR) until disease progression, relapse, death from any cause, or last follow-up, whichever occurs first, assessed up to 60 months

  4. Relapse rates

    Proportion of patients who experience disease relapse after achieving a complete or partial response.

    Time frame: From the date of first documented response (CR or PR) until disease relapse or last follow-up, whichever occurs first, assessed up to 60 months

  5. Relapse Pattern

    Description of the type and location of disease relapse, including nodal vs extranodal and local vs systemic recurrence

    Time frame: From the date of first documented response (CR or PR) until disease relapse or last follow-up, whichever occurs first, assessed up to 60 months

  6. Incidence of chromosomal rearrangements involving MYC gene and BCL2 gene (so called "double hit lymphoma", representing 60% of HGBL) and/or BCL6 (also called "triple hit lymphoma", representing 20% of HG in Large B-cell Lymphomas.

    Proportion of patients with documented genetic rearrangements of MYC, BCL2, or BCL6 detected at the time of pathologic diagnosis.

    Time frame: At the time of pathologic diagnosis (baseline)

07

Study locations

1 site
  • IRCCS San Raffaele Hospital
    Milan, Italy
08

References and documents

Publications

  • Ferreri AJM, Erbella F, Angelillo P, Pecciarini L, Bongiovanni L, Nonis A, Cangi MG, Ponti MV, Saliani L, Fiore P, Bruno-Ventre M, Girlanda S, Marino F, Flospergher E, Cassanello G, Palumbo F, Calimeri T, Ponzoni M. Three-Hour Infusion of Methotrexate at 3 g/m2 With or Without Intrathecal Chemotherapy Significantly Reduces CNS Relapses and Improves Survival in Patients With Large B-Cell Lymphomas at Increased CNS Risk. Am J Hematol. 2026 Jun;101(6):1244-1254. doi: 10.1002/ajh.70283. Epub 2026 Mar 15. PubMed 41832699 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Undecided

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jul 2022 to primary completion in Jul 2023, 12 months.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 5, 2025
First posted
Sep 18, 2025
StartActual
Jul 12, 2022
Primary completionActual
Jul 12, 2023
CompletionActual
Jul 12, 2023
Last update
Sep 18, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 18, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07181785
Lead sponsor
Andrés José Maria Ferreri
Responsible party
Andrés José Maria Ferreri (MD & Prof., IRCCS San Raffaele) — Sponsor-investigator
First posted
Sep 18, 2025
Start date
Jul 12, 2022
Primary completion
Jul 12, 2023
Completion
Jul 12, 2023
Last update
Sep 18, 2025

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion